RadNet, Inc.: Form 10-Q for the period ended Mar 31, 2019
Filed with the SEC on May 10, 2019 and accepted by EDGAR at May 10, 2019, 15:27 ET.
Management's discussion and analysis
As filed, 46,223 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and notes thereto for the year ended December 31, 2018 included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission (SEC) on March 18, 2019.
Forward-Looking Statements
This quarterly report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect current views about future events and are based on our currently available financial, economic and competitive data and on current business plans. Actual events or results may differ materially depending on risks and uncertainties that may affect our operations, markets, services, prices and other factors.
In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “assumption” or the negative of these terms or other comparable terminology. Statements in this quarterly report concerning our ability to successfully acquire and integrate new operations, to grow our contract management business, our financial guidance, our future cost saving efforts, our ability to increase business from new equipment or operations and our ability to finance our operations and repay our outstanding indebtedness, are forward-looking statements.
Forward-looking statements are not guarantees of future performance and our actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, the factors included in “Risk Factors,” in our annual report on Form 10-K for the fiscal year ended December 31, 2018 or supplemented by the information in Part II– Item 1A below. You should consider the inherent limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of predictions contained in such forward-looking statements.
These forward-looking statements speak only as of the date when they are made. We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law.
Overview
We are a leading national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States based on number of locations and annual imaging revenue. At March 31, 2019, we operated directly or indirectly through joint ventures with hospitals, 335 centers located in California, Delaware, Florida, Maryland, New Jersey, and New York. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often reducing the cost and amount of care for patients.
Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services. Our multi-modality strategy diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians one location to serve the needs of multiple procedures. Our operations compose a single segment for financial reporting purposes.
We seek to develop leading positions in regional markets in order to leverage operational efficiencies. Our scale and density within selected geographies provides close, long-term relationships with key payors, radiology groups and referring physicians. Each of our facility managers is responsible for managing relationships with local physicians and payors, meeting our standards of patient service and maintaining profitability. We provide corporate training programs, standardized policies and procedures and sharing of best practices among the physicians in our regional networks.
We derive substantially all of our revenue, directly or indirectly, from fees charged for the diagnostic imaging services performed at our facilities. The following table shows our facilities in operation and revenues for the three months ended March 31, 2019 and March 31, 2018:
| Three Months Ended March 31, 2019 | 2018 | |
|---|---|---|
| Facilities in operation | 335 | 300 |
| Net revenues (millions) | $271.5 | $231.4 |
Our revenue is derived from a diverse mix of payors, including private payors, managed care capitated payors and government payors. We believe our payor diversity mitigates our exposure to possible unfavorable reimbursement trends within any one payor class. In addition, our experience with capitation arrangements over the last several years has provided us with the expertise to manage utilization and pricing effectively, resulting in a predictable stream of revenue. The Company’s total net revenues during the three ended March 31, 2019 and 2018 are presented in the table below based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in thousands):
| Three Months Ended March 31, 2019 | 2018 | |
|---|---|---|
| Commercial insurance | $151,678 | $126,225 |
| Medicare | 54,199 | 44,076 |
| Medicaid | 7,120 | 6,048 |
| Workers' compensation/personal injury | 11,027 | 8,431 |
| Other patient revenue | 5,835 | 5,606 |
| Management fee revenue | 2,117 | 3,677 |
| Teleradiology and Software revenue | 4,386 | 3,816 |
| Other | 6,310 | 6,289 |
| Net service fee revenue | 242,672 | 204,168 |
| Revenue under capitation arrangements | 28,877 | 27,224 |
| Total net revenue | $271,549 | $231,392 |
We typically experience some seasonality to our business. During the first quarter of each year we generally experience the lowest volumes of procedures and the lowest level of revenue for any quarter during the year. This is primarily the result of two factors. First, our volumes and revenue are typically impacted by winter weather conditions in our northeastern operations. It is common for snowstorms and other inclement weather to result in patient appointment cancellations and, in some cases, imaging center closures. Second, in recent years, we have observed greater participation in high deductible health plans by patients. As these high deductibles reset in January for most of these patients, we have observed that patients utilize medical services less during the first quarter, when securing medical care will result in significant out-of-pocket expenditures.
During the first quarter of 2018, unusually severe winter weather conditions in our northeastern and mid-Atlantic operations, which represent slightly over 50% of our total revenue, impacted significantly our operating results, and consequently our results for the three months ended March 31, 2018. Based on our experience we do not believe that lost imaging slots in one quarter are made up later in the quarter or in subsequent quarters.
Investment, Acquisition, and Joint Venture Activity
We have developed our medical imaging business through a combination of organic growth, equity investments, acquisitions and joint venture formations. The information below updates our activity of such matters contained in our annual report on Form 10-K for the year ended December 31, 2018.
Equity Investments
Medic Vision:
On March 24, 2017, we acquired an initial 12.5% equity interest in Medic Vision – Imaging Solutions Ltd for $1.0 million. We also received an option to exercise warrants to acquire up to an additional 12.5% equity interest for $1.4 million within one year from the initial share purchase date, if exercised in full. On March 1, 2018 we exercised our warrant in part and acquired an additional 1.96% for $200,000. Our initial equity interest has been diluted to 12.25% and our total equity investment stands at 14.21%. No impairment in our investment was identified as of the three months ended March 31, 2019.
Turner Imaging:
Turner Imaging Systems, based in Utah, develops and markets portable X-ray imaging systems that provide a user the ability to acquire X-ray images wherever and whenever they are needed. On February 1, 2018, we purchased 2.1 million preferred shares in Turner Imaging Systems for $2.0 million. On January 1, 2019 we funded a convertible promissory note in the amount of $143,000 that will convert to additional preferred shares no later than December 21, 2019. No impairment in our investment was identified for the three months ended March 31, 2019.
Facility acquisitions
On February 1, 2019 our majority owned subsidiary, West Valley Imaging Group, LLC ("WVIG") completed its acquisition of certain assets of West Valley Imaging Center, LLC ("West Valley"), consisting of a single multi-modality imaging center located in West Hills, CA for purchase consideration of $3.0 million which was initially funded by the Company. We have made a fair value determination of the acquired assets and approximately $300,000 in equipment and fixed assets, $7,000 in other assets, $200,000 in intangible assets and $2.5 million in goodwill were recorded. Subsequent to the transaction, our partner in WVIG, Cedars Sinai Medical Center, contributed $750,000 in cash to maintain its 25% economic interest in the venture.
Joint venture formations
On February 13, 2019 we formed a wholly owned subsidiary, Ventura County Imaging Group, LLC ("VCIG"). On March 1, 2019, Dignity Health joined as a venture partner. Total agreed contribution of both parties was $10.4 million of cash and assets with RadNet contributing $4.3 million in assets for a 60% economic interest and Dignity Health contributing $6.1 million in cash and assets for a 40% economic interest. For its contribution, RadNet transferred net assets of three wholly owned multi-modality imaging centers. Dignity Health contributed approximately $800,000 in assets to acquire 5% economic interest and paid RadNet $5.3 million for an additional 35% economic interest. RadNet maintains controlling economic interest in VCIG and fully consolidates the results into our financial statements.
Sale of joint venture interest
On April 1, 2017, we formed in conjuncture with Cedars Sinai Medical Center (“CSMC”) the Santa Monica Imaging Group, LLC (“SMIG”), consisting of two multi-modality imaging centers located in Santa Monica, CA with RadNet holding a 40% economic interest and CSMC holding a 60% economic interest. RadNet accounts for our share of the venture under the equity method. On January 1, 2019, CSMC purchased from the company, an additional five percent economic interest in SMIG valued at $134,000. As a result of the transaction, our economic interest in SMIG has been reduced to 35%. We recorded a loss of $2,000 on the transaction.
Joint venture investment and financial information
The following table is a summary of our investment in joint ventures during the quarter ended March 31, 2019 (in thousands):
| Balance as of December 31, 2018 | $37,973 |
| Equity in earnings in these joint ventures | 1,873 |
| Sale of ownership interest | (134) |
| Balance as of March 31, 2019 | $39,712 |
We charged management service fees from the centers underlying these joint ventures of approximately $2.1 million and $3.4 million for the quarters ended March 31, 2019 and 2018, respectively. We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures.
The following table is a summary of key balance sheet data for these joint ventures as of March 31, 2019 and December 31, 2018 and income statement data for the three months ended March 31, 2019 and 2018 (in thousands):
| Balance Sheet Data: | March 31, 2019 | December 31, 2018 |
|---|---|---|
| Current assets | $33,301 | $28,317 |
| Noncurrent assets | 59,804 | 45,912 |
| Current liabilities | (8,244) | (4,300) |
| Noncurrent liabilities | (15,881) | (4,898) |
| Total net assets | $68,980 | $65,031 |
| Book value of RadNet joint venture interests | $31,738 | $30,030 |
| Cost in excess of book value of acquired joint venture interests | 7,974 | 7,943 |
| Total value of Radnet joint venture interests | $39,712 | $37,973 |
| Total book value of other joint venture partner interests | $37,242 | $35,001 |
32
| Income statement data for the three months ended March 31, | 2018 | 2017 |
|---|---|---|
| Net revenue | $27,254 | $44,546 |
| Net income | $3,952 | $6,250 |
Critical Accounting Policies
The Securities and Exchange Commission defines critical accounting estimates as those that are both most important to the portrayal of a company’s financial condition and results of operations and require management’s most difficult, subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. In Note 2 to our consolidated financial statements in this quarterly report and in our annual report on Form 10-K for the year ended December 31, 2018, we discuss our significant accounting policies, including those that do not require management to make difficult, subjective or complex judgments or estimates. The most significant areas involving management’s judgments and estimates are described below.
Revenues
Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.
As it relates to BRMG centers, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by BRMG as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees from BRMG. As it relates to non-BRMG centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.
Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.
Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.
Deferred Financing Costs
Costs of financing are deferred and amortized using the effective interest rate method. Deferred financing costs, net of accumulated amortization, were $1.2 million and $1.4 million, as of March 31, 2019 and December 31, 2018, respectively and related to our line of credit. See Note 6, Revolving Credit Facility and Notes Payable for more information.
Property and Equipment
Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation of property and equipment is performed using the straight-line method over the estimated useful lives of the assets acquired, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred.
Accounts Receivable
Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. Receivables generally are collected within industry norms for third-party payors. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience.
Depreciation and Amortization of Long-Lived Assets
We depreciate our long-lived assets over their estimated economic useful lives with the exception of leasehold improvements where we use the shorter of the assets useful lives or the lease term of the facility for which these assets are associated. We estimate the economic useful lives of assets, other than leasehold improvements, to be between 3 and 15 years depending on the type of asset.
Income Taxes
Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income, including tax planning strategies, in determining whether our net deferred tax assets are more likely than not to be realized.
Goodwill and Indefinite Lived Intangibles
Goodwill at March 31, 2019 totaled $424.3 million. Indefinite Lived Intangible Assets at March 31, 2019 were $9.9 million and are associated with the value of certain trade name intangibles. Goodwill and trade name intangibles are recorded as a result of business combinations. When we determine the carrying value of goodwill exceeds its fair value an impairment charge would be recognized and should not exceed the total amount of goodwill allocated to that reporting unit. We tested goodwill for impairment on October 1, 2018. During the review we noted our Teleradiology unit, Imaging On Call, (IOC), experienced a reduction of professional medical group clients and a contract with a major local health provider during 2018. This affected its estimated fair value and resulted in impairment charges to our the reporting unit of $3.9 million for the twelve months ended December 31, 2018, with goodwill representing $3.8 million of the total and the remainder being its trade name of approximately $100,000. We have not identified any indicators of impairment through March 31, 2019.
Long-Lived Assets
We evaluate our long-lived assets (property and equipment) and intangibles, other than goodwill, for impairment whenever indicators of impairment exist. To evaluate the long-lived assets our management estimates the undiscounted future cash flows expected to be derived from the asset. The accounting standards require that if the sum of the undiscounted expected future cash flows from a long-lived asset or definite-lived intangible is less than the carrying value of that asset, an asset impairment charge must be recognized. The amount of the impairment charge is calculated as the excess of the asset’s carrying value over its fair value, which generally represents the discounted future cash flows from that asset or in the case of assets we expect to sell, at fair value less costs to sell. No indicators of impairment were identified with respect to our long-lived assets as of March 31, 2019.
Leases
We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long term operating lease liability in our consolidated balance sheets. Finance leases are included in property and equipment, current finance lease liability, and long-term finance lease liability in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have elected to account for the components as a single lease component, as permitted. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. See Note 5, Leases, for more information.
Equity Based Compensation
We have one long-term incentive plan that we adopted in 2006 and which we first amended and restated as of April 20, 2015, and again on March 9, 2017 (the “Restated Plan”). The Restated Plan was approved by our stockholders at our annual stockholders meeting on June 8, 2017. We have reserved for issuance under the Restated Plan 14,000,000 shares of common stock. We can issue options, stock awards, stock appreciation rights, stock units and cash awards under the Restated Plan. Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options and warrants generally vest over three to five years and expire five to ten years from date of grant. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. See Note 7 Stock-Based Compensation for more information.
Recent Accounting Standards
See Note 3, Recent Accounting and Reporting Standards, for further information.
Results of Operations
The following table sets forth, for the three months ended March 31, 2019, the percentage that certain items in the statements of operations bears to total net revenue, and for the three months ended March 31, 2018, the percentage that certain items in the statements of operations bears to revenue, net of contractual allowances and discounts and inclusive of revenue under capitation contracts.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS EXCEPT SHARE DATA)
(unaudited)
| NET REVENUE | Three Months Ended March 31 2019 | 2018 |
|---|---|---|
| Service fee revenue | 89.4% | 88.2% |
| Revenue under capitation arrangements | 10.6% | 11.8% |
| Total revenue | 100.0% | 100.0% |
| OPERATING EXPENSES | ||
| Cost of operations, excluding depreciation and amortization | 89.5% | 93.2% |
| Depreciation and amortization | 7.2% | 7.7% |
| Loss (gain) on sale and disposal of equipment | 0.4% | (0.8)% |
| Severance costs | 0.2% | 0.3% |
| Total operating expenses | 97.3% | 100.4% |
| INCOME (LOSS) FROM OPERATIONS | 2.7% | (0.4)% |
| OTHER INCOME AND EXPENSES | ||
| Interest expense | 4.5% | 4.3% |
| Equity in earnings of joint ventures | (0.7)% | (1.3)% |
| Total other expenses | 3.8% | 3.1% |
| LOSS BEFORE INCOME TAXES | (1.2)% | (3.4)% |
| Benefit from income taxes | 0.5% | 1.1% |
| NET LOSS | (0.7)% | (2.4)% |
| Net income attributable to noncontrolling interests | 0.7% | 0.8% |
| NET LOSS ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS | (1.4)% | (3.2)% |
Three Months Ended March 31, 2019 Compared to the Three Months Ended March 31, 2018
Total Net Revenue
Total net revenue for the three months ended March 31, 2019 was $271.5 million compared to $231.4 million for the three months ended March 31, 2018, an increase of $40.2 million or 17.4%.
Total net revenue, including only centers which were in operation throughout the first quarters of both 2019 and 2018 increased 3.2% or $7.3 million. The increase mainly resulted from higher MRI and CT procedure volumes, which increased 3.2% and 4.5%, respectively, over the same period last year. Contributing to the boost was improved equipment utilization across the company. This comparison excludes revenue contributions from centers that were acquired or divested subsequent to January 1, 2018. For the three months ended March 31, 2019, net service fee revenue from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $36.1 million. For the three months ended March 31, 2018, net service fee revenue from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $3.2 million.
Operating Expenses
Total operating expenses for the three months ended March 31, 2019 increased approximately $32.0 million, or 13.8%, from $232.3 million million for the three months ended March 31, 2018 to $264.3 million for the three months ended March 31, 2019. The following table sets forth our cost of operations and total operating expenses for the three months ended March 31, 2019 and 2018 (in thousands):
| Three Months Ended March 31, 2019 | 2018 | |
|---|---|---|
| Salaries and professional reading fees, excluding stock-based compensation | $153,400 | $133,916 |
| Stock-based compensation | 4,538 | 3,745 |
| Building and equipment rental | 25,266 | 21,184 |
| Medical supplies | 9,838 | 9,534 |
| Other operating expenses * | 50,014 | 47,256 |
| Cost of operations | 243,056 | 215,635 |
| Depreciation and amortization | 19,620 | 17,856 |
| Loss (gain) on sale and disposal of equipment | 971 | (1,936) |
| Severance costs | 631 | 726 |
| Total operating expenses | $264,278 | $232,281 |
* Includes billing fees, office supplies, repairs and maintenance, insurance, business tax and license, outside services, telecom, utilities, marketing, travel and other expenses.
Salaries and professional reading fees, excluding stock-based compensation and severance
Salaries and professional reading fees increased $19.5 million, or 14.6%, to $153.4 million for the three months ended March 31, 2019 compared to $133.9 million for the three months ended March 31, 2018.
Salaries and professional reading fees, limited to only centers in operation throughout the first quarters of both 2019 and 2018, increased $4.7 million or 3.6%. Of the total rise of 3.6%, 2.5% was precipitated by increased physician cost due to greater procedure volume and the remainder related to added personnel and existing employee wage and benefit increases in support of operations. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2018. For the three months ended March 31, 2019, salaries and professional reading fees from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $17.1 million. For the three months ended March 31, 2018, salaries and professional reading fees from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was approximately $2.3 million.
Stock-based compensation
Stock-based compensation increased $793,900, or 14.3% to approximately $4.5 million for the three months ended March 31, 2019 compared to $3.7 million for the three months ended March 31, 2018. This increase was driven by the higher fair value of RSA’s awarded and vested in the first quarter of 2018 as compared to RSA’s awarded and vested in the prior year’s first quarter.
Building and equipment rental
Building and equipment rental expenses increased $4.1 million or 19.3%, to $25.3 million for the three months ended March 31, 2019 compared to $21.2 million for the three months ended March 31, 2018.
Building and equipment rental expenses for same store centers which were in operation throughout the first quarters of 2019 and 2018, increased $1.2 million or 5.7%, mainly related to additional radiology equipment leases in support of imaging operations. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2018. For the three months ended March 31, 2019, building and equipment rental expenses from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $3.6 million. For the three months ended March 31, 2018, building and equipment rental expenses from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was approximately $637,700.
Medical supplies
Medical supplies expense increased $303,800, or 3.2%, to $9.8 million for the three months ended March 31, 2019 compared to $9.5 million for the three months ended March 31, 2018.
Medical supplies expenses, including only those centers which were in operation throughout the first quarters of both 2019 and 2018, decreased $924,100 or 9.9%. Savings were attributable to favorable restructuring of medical supplier contracts and price reductions for contrasting imaging agents employed in advanced radiology modalities. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2018. For the three months ended March 31, 2019, medical supplies expenses from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $1.4 million. For the three months ended March 31, 2018, medical supplies expense from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $169,500.
Other operating expenses
Other operating expenses increased $2.8 million, or 3.9%, to $50.0 million for the three months ended March 31, 2019 compared to $47.3 million for the three months ended March 31, 2018.
Other operating expenses, limited to centers which were in operation throughout the first quarters of both 2019 and 2018, decreased $4.4 million, or 9.4%, driven by reductions in telecommunication, insurance, software and service contracts rates stemming from supplier renegotiations. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2018. For the three months ended March 31, 2019, other operating expense from centers that were acquired or divested subsequent January 1, 2018 and excluded from the above comparison was $7.9 million. For the three months ended March 31, 2018, other operating expense from centers that were acquired or divested subsequent to January 1, 2018 was $778,100.
Depreciation and amortization
Depreciation and amortization increased $1.8 million, or 9.9%, to $19.6 million for the three months ended March 31, 2019 compared to $17.9 million for the three months ended March 31, 2018.
Depreciation and amortization, inclusive of only centers in operation during the first quarters of both 2018 and 2017, increased $1,298,300 or 7.4%. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2018. For the three months ended March 31, 2019, depreciation expense from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $3.4 million. For the three months ended March 31, 2018, depreciation and amortization from centers that were acquired or divested subsequent to January 1, 2018 and excluded from the above comparison was $322,100.
Gain on sale and disposal of equipment
We recorded a loss on the disposal of approximately $971,400 for the three months ended March 31, 2019. We recorded a gain on sale of equipment of approximately $1.9 million for the three months ended March 31, 2018.
Severance Costs
We incurred severance expenses of $630,700 for the three months ended March 31, 2019 and $725,600 for the three months ended March 31, 2018.
Interest expense
Interest expense increased approximately $2.3 million, or 22.5%, to $12.3 million for the three months ended March 31, 2019 compared to $10.0 million for the three months ended March 31, 2018. Interest expense for the three months ended March 31, 2019 and March 31, 2018 included $975,000 and $979,000, respectively, of combined non cash amortization of deferred loan costs, discount on issuance of debt and incidental financing charges. Excluding these amounts for the three months ended March 31, 2019 compared to the three months ended March 31, 2018, interest expense increased $2.3 million, or 24.9%. The main drivers behind the increase were the interest payments on assumed debt of the New Jersey Imaging Network and higher loan interest stemming from interest rate hikes during 2018. See “Liquidity and Capital Resources” below for more details on our credit facilities.
Equity in earnings from unconsolidated joint ventures
For the period ended March 31, 2019 we recognized equity in earnings from unconsolidated joint ventures in the amount of $1.8 million. For the period ended March 31, 2018 we recognized equity in earnings from unconsolidated joint ventures of $3.0 million.
Provision for income taxes
We recorded an income tax benefit of $1.2 million, or an effective tax rate of 39.0%, for the three months ended March 31, 2019 compared to income tax benefit for the three months ended March 31, 2018 of $2.5 million, or an effective tax rate of 22.4%. The income tax rates for the three months ended March 31, 2019 diverge from the federal statutory rate due to (i) noncontrolling interests due to the controlled partnerships; (ii) effects of state income taxes; (iii) excess tax benefits attributable to share-based compensation; and adjustment associated with uncertain tax positions.
Adjusted EBITDA
We use both GAAP and non-GAAP metrics to measure our financial results. One non-GAAP measure we believe assists us is Adjusted EBITDA. We believe that, in addition to GAAP metrics, these non-GAAP metrics assist us in measuring our cash generated from operations and ability to service our debt obligations. We believe this information is useful to investors and other interested parties because we are highly leveraged and our non-GAAP metrics remove non-cash and certain other charges that occur in the affected period and provide a basis for measuring the Company's financial condition against other quarters.
We define Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and excluding losses or gains on the disposal of equipment, other income or loss, loss on debt extinguishments, bargain purchase gains and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to noncontrolling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taking place during the period.
Adjusted EBITDA is a non-GAAP financial measure used as an analytical indicator by us and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.
Adjusted EBITDA is most comparable to the GAAP financial measure, net income (loss) attributable to RadNet, Inc. common stockholders. The following is a reconciliation of GAAP net income (loss) attributable to RadNet, Inc. common stockholders to Adjusted EBITDA for the three ended March 31, 2019 and 2018, respectively.
| Three Months Ended March 31, 2019 | 2018 | |
|---|---|---|
| Net loss attributable to RadNet, Inc. common stockholders | $(3,733) | $(7,338) |
| Plus other expenses | 1 | |
| Plus interest expense | 12,295 | 10,039 |
| Plus severance costs | 631 | 726 |
| Plus loss/less (gain) on sale and disposal of equipment | 971 | (1,936) |
| Plus depreciation and amortization | 19,620 | 17,856 |
| Plus non-cash employee stock-based compensation | 4,538 | 3,745 |
| Plus gain on sale of equipment attributable to noncontrolling interest | — | 440 |
| Less benefit from income taxes | (1,230) | (2,497) |
| Adjusted EBITDA | $33,092 | $21,036 |
Liquidity and Capital Resources
The following table is a summary of key balance sheet data as of March 31, 2019 and December 31, 2018 and income statement data for the three months ended March 31, 2019 and 2018 (in thousands):
| Balance Sheet Data: | March 31, 2019 | December 31, 2018 |
|---|---|---|
| Cash and cash equivalents | $10,428 | $10,389 |
| Accounts receivable | 156,767 | 148,919 |
| Working capital (exclusive of current operating lease liabilities) | (19,917) | (30,827) |
| Stockholders' equity | 213,538 | 200,253 |
| Income statement data for the three months ended March 31, | 2019 | 2018 |
|---|---|---|
| Total net revenue | $271,549 | $231,392 |
| Net loss attributable to RadNet common stockholders | (3,733) | (7,338) |
We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations. In addition to operations, we require a significant amount of capital for the initial start-up and development of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment. Because our cash flows from operations have been insufficient to fund all of these capital requirements, we have depended on the availability of financing under credit arrangements with third parties.
Based on our current level of operations, we believe that cash flow from operations and available cash, together with available borrowings from our senior secured credit facilities, will be adequate to meet our liquidity needs. Our future liquidity requirements will be for working capital, capital expenditures, debt service and general corporate purposes. Our ability to meet our working capital and debt service requirements, however, is subject to future economic conditions and to financial, business and other factors, many of which are beyond our control. If we are not able to meet such requirements, we may be required to seek additional financing. There can be no assurance that we will be able to obtain financing from other sources on terms acceptable to us, if at all.
On a continuing basis, we also consider various transactions to increase shareholder value and enhance our business results, including acquisitions, divestitures and joint ventures. These types of transactions may result in future cash proceeds or payments but the general timing, size or success of any acquisition, divestiture or joint venture effort and the related potential capital commitments cannot be predicted. We expect to fund any future acquisitions primarily with cash flow from operations and borrowings, including borrowing from amounts available under our senior secured credit facilities or through new equity or debt issuances.
We and our subsidiaries or affiliates may from time to time, in our sole discretion, purchase, repay, redeem or retire any of our outstanding debt or equity securities in privately negotiated or open market transactions, by tender offer or otherwise.
Sources and Uses of Cash
Cash provided by operating activities was $26.9 million and $24.3 million for the three months ended March 31, 2019 and March 31, 2018, respectively.
Cash used in investing activities was $35.2 million and $29.8 million for the three months ended March 31, 2019 and 2018, respectively. For the three months ended March 31, 2019, we purchased property and equipment for approximately $32.9 million and acquired imaging facilities for $3.0 million.
Cash provided by financing activities was $8.3 million for the three months ended March 31, 2019 and cash used in financing activities was $10.8 million for the three months ended March 31, 2018. The cash provided by financing activities for the three months ended March 31, 2019, was mainly due to borrowings on our Barclays Revolving Credit Facility.
In 2018 we entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. The aggregate gross amount factored under these facilities was $20.5 million and the cost of factoring such accounts receivable was $440,000. At March 31, 2019 we have $17.8 million remaining to be collected on these agreements. We do not utilize factoring arrangements as an integral part of our financing for working capital.
Senior Secured Credit Facilities
At March 31, 2019, our credit facilities were comprised of one tranche of term loans (“First Lien Term Loans”) and a revolving credit facility of $117.5 million (the “Barclays Revolving Credit Facility”), both of which are provided pursuant to the Amended and Restated First Lien Credit and Guaranty Agreement dated as of July 1, 2016 (as amended, the “First Lien Credit Agreement”).
At March 31, 2019, our SunTrust credit facilities were comprised of one term loan (the "SunTrust Term Loan") and a revolving credit facility of $30.0 million (the "SunTrust Revolving Credit Facility") both of which are provided pursuant to the SunTrust Restated Credit Agreement (as described in Note 6 in our condensed consolidated financial statement in this quarterly report).
As of March 31, 2019, we were in compliance with all covenants under our credit facilities. Deferred financing costs at March 31, 2019, net of accumulated amortization, was $1.2 million and is specifically related to our Barclays Revolving Credit Facility.
Included in our condensed consolidated balance sheets at March 31, 2019 are $623.1 million of senior secured term loan debt (net of unamortized discounts of $14.3 million) in thousands:
| Face Value | Discount | Total Carrying Value | |
|---|---|---|---|
| First Lien Term Loans | 578,920 | (14,272) | 564,648 |
| SunTrust Term Loan | 58,500 | — | 58,500 |
| Total Term Loans | 637,420 | (14,272) | 623,148 |
We had a balance of $41.0 million under our $117.5 million Barclays Revolving Credit Facility at March 31, 2019 and have reserved an additional $6.9 million for certain letters of credit. The remaining $69.6 million of our Barclays Revolving Credit Facility was available to draw upon as of March 31, 2019. We had no balance under our $30.0 million Suntrust Revolving Credit Facility at March 31, 2019.
For more information on our secured credit facilities see Note 6 in our condensed consolidated financial statements in this quarterly report.
Market risk
As filed, 4,041 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Foreign Currency Exchange Risk: We receive payment for our services exclusively in United States dollars. As a result, our financial results are unlikely to be affected by factors such as changes in foreign currency, exchange rates or weak economic conditions in foreign markets.
We maintain research and development facilities in Prince Edward Island, Canada and Budapest, Hungary for which expenses are paid in the local currency. Accordingly, we do have currency risk resulting from fluctuations between such local currency and the United States Dollar. At the present time, we do not have any foreign currency exchange contracts to mitigate this risk. At March 31, 2019, a hypothetical 1% decline in the currency exchange rates between the U.S. dollar against the Canadian dollar and the Hungarian Forint would have resulted in an annual increase of approximately $35,000 in operating expenses.
Interest Rate Sensitivity: We pay interest on various types of debt instruments to our suppliers and lending institutions. The agreements entail either fixed or variable interest rates. Instruments which have fixed rates are mainly leases on radiology equipment. Variable rate interest obligations relate primarily to amounts borrowed under our outstanding credit facilities. Accordingly, our interest expense and consequently, our earnings, are affected by changes in short term interest rates. However due to our purchase of caps, described below, the effects of interest rate changes are limited.
Interest Rate Sensitivity Barclays First Lien Term Loans
At March 31, 2019, we had $578.9 million outstanding subject to an adjusted Eurodollar election on First Lien Term Loans. We can elect Eurodollar or Base Rate (Prime) interest rate options on amounts outstanding under the First Lien Term Loans.
To mitigate interest rate risk sensitivity, in the fourth quarter of 2016 we entered into two forward interest rate cap agreements (the “2016 Caps”) which were designated at inception as cash flow hedges of future cash interest payments. The 2016 Caps are designed to provide a hedge against interest rate increases. Under these arrangements, we purchased a cap on 3 month LIBOR at 2.0%. At March 31, 2019, our effective 3 month LIBOR was 2.78%. The 2016 Caps have a notional amount of $150,000,000 and $350,000,000 and will mature in September and October 2020. We are liable for a $5.3 million premium to enter into the caps which is being accrued over the life of the 2016 Caps. See Note 2, Significant Accounting Policies, for further information.
A hypothetical 1% increase in the adjusted Eurodollar rates under the First Lien Credit Agreement over the rates experienced in 2018 would, after considering the effects of the 2016 Caps, result in an increase of $789,200 in annual interest expense and a corresponding decrease in income before taxes. At March 31, 2019, an additional $49.3 million million in debt instruments is tied to the prime rate. A hypothetical 1% increase in the prime rate would result in an annual increase in interest expense of approximately $492,700 and a corresponding decrease in income before taxes. These amounts are determined by considering the impact of the hypothetical interest rates on the borrowing costs and cap agreements.
Interest Rate Sensitivity SunTrust Term Loan
At March 31, 2019, we had $58.5 million outstanding subject to an adjusted Eurodollar election on the SunTrust Restated Credit Agreement. We can elect Eurodollar or Base Rate (Prime) interest rate options on amounts outstanding under the SunTrust Restated Credit Agreement.
At March 31, 2019, our effective LIBOR rate plus applicable margin was 4.85%. A hypothetical 1% increase in the adjusted Eurodollar rates under the SunTrust Restated Credit Agreement over the rates experienced in 2018 would result in an increase of approximately $585,000 in annual interest expense and a corresponding decrease in income before taxes. No amounts are tied to the prime rate under the SunTrust Restated Agreement.
Controls and procedures
As filed, 1,586 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
We maintain controls and procedures designed to ensure that we are able to collect the information we are required to disclose in the reports we file with the SEC, and to process, summarize and disclose this information within the time periods specified in the rules of the SEC. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has conducted an evaluation of the design and operation of our “disclosure controls and procedures” as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective as of the end of the period covered by this report to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.
Changes in Internal Control over Financial Reporting
As of January 1, 2019, we adopted the new lease standard ASU 2016-02 and implemented internal control procedures and key system functionality to enable the preparation of financial information. Other than the addition of these procedures, there has been no significant change in our internal control over financial reporting during the three months ended March 31, 2019 that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.
Risk factors
As filed, 465 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
For information about the risks and uncertainties related to our business, please see the risk factors described in our annual report on Form 10-K for the year ended December 31, 2018. The risks described in our Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-01-01 to 2019-03-31 | $271.5m | us-gaap:Revenues |
| Cost of revenue | 3 months2019-01-01 to 2019-03-31 | $243.1m | us-gaap:CostOfRevenue |
| Operating income | 3 months2019-01-01 to 2019-03-31 | $7.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2019-01-01 to 2019-03-31 | −$1.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-01-01 to 2019-03-31 | −$3.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-01-01 to 2019-03-31 | −$0.08 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-01-01 to 2019-03-31 | −$0.08 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months2019-01-01 to 2019-03-31 | $26.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2019-01-01 to 2019-03-31 | $32.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-03-31 | $10.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-03-31 | $216.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-03-31 | $1.53bn | us-gaap:Assets |
| Current liabilities | At period end2019-03-31 | $300.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-03-31 | $1.31bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-03-31 | $135.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-19-006534. Last ingested by Listed: Nov 15, 2026, 00:07 ET. Listed shows no prices and gives no investment advice.